计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
O129260-1mg |
1mg |
现货 ![]() |
| |
O129260-5mg |
5mg |
现货 ![]() |
| |
O129260-10mg |
10mg |
现货 ![]() |
| |
O129260-25mg |
25mg |
期货 ![]() |
| |
O129260-50mg |
50mg |
期货 ![]() |
| |
O129260-100mg |
100mg |
期货 ![]() |
|
别名 | 奥泼佐米 |
---|---|
英文别名 | ONX-0912 | PR-047 | J-690398 | N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide | SWZXEVABPLUDIO-WSZYKNRRSA-N | DTXSID201025950 |
规格或纯度 | Moligand™, ≥98% |
英文名称 | Oprozomib (ONX 0912) |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 抑制剂 |
作用机制 | 26S 蛋白质体抑制剂 |
产品介绍 |
Oprozomib (ONX 0912)是一种口服生物有效的抑制剂,抑制20S proteasome(20S蛋白酶体)β5/LMP7的CT-L活性,IC50为36 nM/82 nM。 Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. |
ALogP | 1.1 |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 504769954 |
---|---|
分子类型 | 小分子 |
IUPAC Name | N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide |
INCHI | InChI=1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)/t17-,18-,19-,25+/m0/s1 |
InChi Key | SWZXEVABPLUDIO-WSZYKNRRSA-N |
Canonical SMILES | CC1=NC=C(S1)C(=O)NC(COC)C(=O)NC(COC)C(=O)NC(CC2=CC=CC=C2)C(=O)C3(CO3)C |
Isomeric SMILES | CC1=NC=C(S1)C(=O)N[C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@]3(CO3)C |
PubChem CID | 25067547 |
分子量 | 532.61 |
溶解性 | ≥26.6 mg/mL in DMSO; insoluble in H2O; ≥2.77 mg/mL in EtOH with gentle warming and ultrasonic |
---|---|
分子量 | 532.600 g/mol |
XLogP3 | 1.100 |
氢键供体数Hydrogen Bond Donor Count | 3 |
氢键受体数Hydrogen Bond Acceptor Count | 9 |
可旋转键计数Rotatable Bond Count | 14 |
精确质量Exact Mass | 532.199 Da |
单同位素质量Monoisotopic Mass | 532.199 Da |
拓扑极表面积Topological Polar Surface Area | 176.000 Ų |
重原子数Heavy Atom Count | 37 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 825.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 4 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
Purity(HPLC) | 98-100(%) |
---|---|
Oxygen by Elemental Analysi | 20.1-21.5(%) |
Nitrogen by Elemental Analysis | 9.8-11.1(%) |
Carbon by Elemental Analysis | 54.7-56.8(%) |
Appearance(O129260) | White to off-white solid |
NMR spectrum | Conforms to Structure |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
批号(Lot Number) | 证书类型 | 日期 | 货号 |
---|---|---|---|
![]() |
分析证书 | 23-11-02 | O129260 |
![]() |
分析证书 | 23-11-02 | O129260 |
![]() |
分析证书 | 23-11-02 | O129260 |
![]() |
分析证书 | 23-11-02 | O129260 |
![]() |
分析证书 | 23-11-02 | O129260 |
![]() |
分析证书 | 23-11-02 | O129260 |
![]() |
分析证书 | 23-11-02 | O129260 |
![]() |
分析证书 | 23-11-02 | O129260 |
![]() |
分析证书 | 23-11-02 | O129260 |
![]() |
分析证书 | 23-11-02 | O129260 |
1. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ et al.. (2009) Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).. J Med Chem, 52 (9): (3028-38). [PMID:19348473] [10.1021/op500134e] |
2. Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC. (2010) A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.. Blood, 116 (23): (4906-15). [PMID:20805366] [10.1021/op500134e] |
3. Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. (2012) Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.. Clin Cancer Res, 18 (20): (5639-49). [PMID:22929803] [10.1021/op500134e] |
4. Kale AJ, Moore BS. (2012) Molecular mechanisms of acquired proteasome inhibitor resistance.. J Med Chem, 55 (23): (10317-27). [PMID:22978849] [10.1021/op500134e] |